Therapeutic effects of percutaneous coronary intervention on acute myocardial infarction complicated with multiple organ dysfunction syndrome

Abstract

Objective:To evaluate the clinical efficacy of percutaneous coronary intervention (PCI) on patients with acute myocardial infarction (AMI) complicated with multiple organ dysfunction syndrome (MODS).Methods:A total of 216 patients with AMI complicated with MODS enrolled from January 2016 to March 2018 were divided into a PCI group (n=98) and a drug treatment group (n=118). The baseline clinical data, the incidence of each dysfunction organ, the number of dysfunctional organs and the mortality were compared between the two groups.Results:The number of patients with ST-segment elevation AMI in the PCI group was higher than in the drug treatment group, and the rate of patients with non-ST-segment elevation AMI was lower than in the drug treatment group (P<0.05). The use of temporary pacemakers and IABP was similar between the two groups (P>0.05). The recanalization rate in PCI group was much higher than that in the drug treatment group (P<0.05). The two groups had similar incidence of organ dysfunction in the heart, lungs, kidneys, stomach and intestine, etc. and the PCI group had lower organ dysfunction incidence in the liver, brain and hematological system than the drug treatment group (P<0.05). The dysfunction incidence rate of two organs was higher in PCI group than in drug treatment group (P<0.05), the dysfunction incidence rate of 3 organs was similar between the two groups, and the dysfunction incidence rate of three organs or more was significantly lower in PCI group than in drug treatment group (P<0.05).Conclusion:Despite the high risk and high mortality of patients with AMI plus MODS, clinical improvement can still be achieved when effective PCI is performed.

Cardio protective effect of nicorandil in reperfusion injury among patients undergoing primary percutaneous coronary intervention

“…The prevalence rate of NRP in STEMI patients who underwent primary PCI is >30% and can cause adverse clinical outcome, including "arrhythmias, heart failure, sudden cardiac death" and other major cardiovascular complications. 9,10 The treatment of MI involves both pharmacological and non-pharmacological approaches. Among the non-pharmacological treatment, primary PCI is the gold standard treatment used in STEMI patients.…”

“…The prevalence rate of NRP in STEMI patients who underwent primary PCI is >30% and can cause adverse clinical outcome, including “arrhythmias, heart failure, sudden cardiac death” and other major cardiovascular complications. 9 , 10 …”